Phase 3Recruiting

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

A Phase 3 Randomized Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

Sponsor
Qilu Pharmaceutical Co., Ltd. (Industry)
Enrollment
228 planned
Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
QLS32015; Pomalidomide; Selinexor; Dexamethasone
Ages
adults, older adults
Registry
NCT07138209

Full record on ClinicalTrials.gov

From the registry

The purpose of this study is to compare the safety and efficacy of QLS32015 with Pd/Sd for the treatment of relapsed or refractory multiple myeloma.

Primary outcomes

  • Progression-free Survival (PFS)

History

  1. Study completion expected

  2. Primary completion expected

  3. Last registry update

  4. Started

  5. Registered